Bionomics Aktie
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 7 | 0 | 24 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,04 | 0,00 | 0,00 |
Bilanz (in Mio. AUD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 8 | 31 | 42 | 20 | 13 |
| Summe Anlagevermögen | 26 | 23 | 23 | 23 | 15 |
| Summe Aktiva | 34 | 54 | 65 | 43 | 28 |
Bilanz (in Mio. AUD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 12 | 1 | 1 | 1 | 0 |
| Summe Fremdkapital | 22 | 7 | 8 | 10 | 11 |
| Summe Eigenkapital | 13 | 48 | 57 | 33 | 17 |
| Summe Passiva | 34 | 54 | 65 | 43 | 28 |
Adresse
| 200 Greenhill Road, 5063 Eastwood | |
| Telefon | +61 (8) 8150-7400 |
| Internet | http://www.bionomics.com.au |
Management
|
Adrian Hinton
Financial Controller |
|
Alan David Fisher
Independent Non-Executive Chairman |
|
David Ian Wilson
Independent Non-Executive Director |
|
Jane Ryan
Independent Non-Executive Director |
|
Julie Kerner
Senior Vice President-Business Operations |
|
Liz Doolin
Senior Vice President-Clinical Development |
|
Mark A. Smith
Chief Medical Officer |
|
Matthew Brennan
VP-Business Development & Scientific Evaluation |
|
Peter Miles Winston Davies
Independent Non-Executive Director |
|
Rajeev Chandra
Secretary |
|
Spyridon Papapetropoulos
President, Chief Executive Officer & Director |
|
Timothy M. Cunningham
Chief Financial Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
